Compare Axon Enterprise Inc (AXON) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axon Enterprise Inc vs BIO-TECHNE Corp — how do they compare? Axon Enterprise Inc trades at $636.99 (market cap $48.44B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Axon Enterprise Inc is far larger — about 4.3× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Axon Enterprise Inc pays none. Which is the better fit depends on your goals.
| AXON | TECH | |
|---|---|---|
Market Cap | $48.44B | $11.24B |
Sector | Technology | Health |
52-Week High | $818.69 | $72.29 |
52-Week Low | $345.94 | $43.31 |
Enterprise Value | $49.59B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Axon Enterprise (AXON) trades at $571.01, up 9.29% with strong momentum following Q2 2026 results showing 35% revenue growth and 10 consecutive quarters above 30% expansion. Technical indicators show bullish moving averages with current price near resistance at $587. The company maintains dominant positioning in public safety technology with accelerating AI and counter-drone business segments driving future growth potential.
Axon presents compelling growth prospects with raised 2026 revenue guidance of 32-34% and expanding software ecosystem, though elevated valuations (P/E 248) and margin pressures from service mix shifts warrant caution. Analyst consensus remains strongly bullish with $685 price target representing 20% upside potential from current levels.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Axon Enterprise Inc
Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.
Read more on AXON →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
